Waters' John Ornell plans to resign from his post as chief financial officer, effective Feb. 1, 2014, after which he will continue to serve the company as an advisor on a part-time basis. Eugene Cassis, who currently is corporate VP of worldwide business development and investor relations, will step into the CFO role on an interim basis when Ornell leaves the position. Cassis has been with the company for 33 years and has an extensive background in the firm's financial, operational, and technical activities. <\/p>\n
RainDance Technologies has appointed Alfred Merriweather as CFO. He most recently served as CFO of Verinata Health prior to its acquisition by Illumina. <\/p>\n
Previously, Merriweather served as CFO and in senior executive positions with several life science and clinical diagnostics companies, including Celera and Monogram Biosciences. <\/p>\n
NuVasive, a medical device company that develops spinal surgical products and procedures, has appointed Greg Lucier to its board of directors. <\/p>\n
Lucier is the chairman and CEO of Life Technologies, which is in the process of being acquired by Thermo Fisher Scientific. He has also held senior management positions at General Electric. <\/p>\n
PerkinElmer has appointed Jon DiVincezo to be president of its Environmental Health business and senior VP of the PerkinElmer. Maurice Tenney, who has led the Environmental Health business for four years, will start in a new position at PerkinElmer overseeing global operations and customer logistics. DiVincenzo will assume the new post on Dec. 2, and will report to Chairman and CEO Robert Friel. Prior to joining PerkinElmer, DiVincenzo served as the President and Chief Executive Officer of Enzymatics, and before that he worked at Millipore for 18 years where he last served as president of the Bioscience division. <\/p>\n
<\/p>\n
See the rest here: Waters' John Ornell plans to resign from his post as chief financial officer, effective Feb. 1, 2014, after which he will continue to serve the company as an advisor on a part-time basis. Eugene Cassis, who currently is corporate VP of worldwide business development and investor relations, will step into the CFO role on an interim basis when Ornell leaves the position. Continue reading
\nGenome Compiler Asks USPTO to Reexamine DNA2.0 Patent in Ongoing Legal Row<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"